Optimizing Patient Outcomes in the Era of PCSK9 Inhibitor Therapeutics

This live symposium will focus on the most current clinical trial data for optimizing patient outcomes in the era of PCSK9 inhibitor therapeutics. Expert faculty will utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision-making. The educational material of this symposium will provide vital information for lipidologsts to improve healthcare outcomes in their patients with statin intolerance, familial hypercholesterolemia and dyslipidemia.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with cardiologists, lipidologists, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with dyslipidemia.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

  1. Review advances in LDL-C science and the role of LDL-C in CVD prevention.
  2. Understand the current ACC/AHA/ESC/NLA guidelines for the management of patients with dyslipidemia.
  3. Analyze extended CVD Outcomes clinical trial data for PCSK9 inhibitor therapeutics.
  4. Apply newer scientific knowledge and data into personalized treatment plans for patients with statin intolerance, familial hypercholesterolemia, and dyslipidemia patients not at LDL-C goal.

FACULTY

Christopher P. Cannon, MD
Professor of Medicine
Harvard Medical School
Executive Director of Cardiometabolic Trials
Baim Institute for Clinical Research
Senior Physician, Cardiovascular Division
Brigham and Women’s Hospital
Boston, MA

Christie M. Ballantyne, MD
Professor of Medicine
Baylor College of Medicine
Center for Cardiovascular Disease Prevention
Houston Methodist DeBakey Heart & Vascular Center
Baylor College of Medicine
Houston, TX, US

Harold E. Bays, MD
Medical Director and President
Louisville Metabolic and Atherosclerosis Research Center
Louisville, KY 

G. Kees Hovingh, MD, PhD, MBA
Department of Vascular Medicine
Academic Medical Center
Amsterdam, Netherlands

James A. Underberg, MD
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease
Director Bellevue Hospital Lipid Clinic
President-Elect National Lipid Association
New York, NY

Disclosure of Conflicts of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

FacultyRelationship Identified With:
Christopher P. Cannon, MD

Consultant/Advisor: Alnylam; Amgen, Inc.; Arisaph Pharmaceuticals, Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline plc.; Kowa Pharmaceuticals America, Inc.; LipoMedix; Merck & Co., Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.

Grant/Research Support: Arisaph Pharmaceuticals, Inc.; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Company; GlaxoSmithKline plc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Takeda Pharmaceuticals U.S.A., Inc.

Christie M. Ballantyne, MD

Consultant/Advisor: Abbott Laboratories; Amarin Corp.; Amgen, Inc.; AstraZeneca; Eli Lilly and Company; Esperion Therapeutics, Inc.; Genzyme Corporation; Ionis Pharmaceuticals; Matinas BioPharma Holdings, Inc.; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Diagnostics; Sanofi-Synthelabo, Inc.

Grant/Research Support: Abbott Laboratories; Amarin Corp.; Amgen, Inc.; Eli Lilly and Company; Esperion Therapeutics, Inc.; Novartis AG; Pfizer Inc.; Otsuka America Pharmaceutical, Inc.; Regeneron Pharmaceuticals, Inc.; Roche Diagnostics; sanofi-aventis U.S. LLC.; Takeda Pharmaceuticals U.S.A., Inc.

Harold E. Bays, MD

Consultant/Advisor: Alnylam, Amgen Inc.; AstraZeneca; Eli Lilly and Company; Esperion Therapeutics, Inc.; Ionis Pharmaceuticals; Janssen Global Services, LLC.; Kowa Pharmaceuticals America, Inc.; Merck & Co., Inc; Moderna Therapeutics; Novartis AG; Procter & Gamble; Regeneron Pharmaceuticals, Inc.; Sanofi; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd.

Grant/Research Support: Alere Inc. Company; Allergan; Amarin Corp.; Amgen Inc.; Arisaph Pharmaceuticals, Inc.; AstraZeneca; Bristol-Meyers Squibb Company; Catabasis; Cymabay Therapeutics, Inc.; Dr. Reddy; Eisai Co., Ltd.; Elcelyx Therapeutics, Inc.; Eli Lilly and Company; Esperion; Ferrer/Chiltern; Gemphire; Gilead; GlaxoSmithKline plc.; Janssen Global Services, LLC.; Johnson and Johnson Services, Inc.; Kowa Pharmaceuticals America, Inc.; Merck & Co., Inc.; Nektar; Nichi-Iko Pharmaceutical Co., Ltd.;, Novartis AG; Novo Nordisk A/S; Orexigen Therapeutics, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Selecta Biosciences, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; TIMI Pharmaceuticals, Inc.

Speaker's Bureau: Amarin Corp.; Amgen Inc.; AstraZeneca; Eisai Co., Ltd.; Orexigen Therapeutics, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.

G. Kees Hovingh, MD, PhD, MBA

Consultant/Advisor: Amgen, Inc; Aegerion Pharmaceuticals Inc.; AstraZeneca; Cerenis Therapeutics; Ionis Pharmaceuticals; Kowa Pharmaceuticals America, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi

James A. Underberg, MD

Consultant/Advisor: Aegerion Pharmaceuticals Inc.; Akcea Therapeutics; Amarin Corp.; Amgen, Inc.; Invitae Corporation; National Lipid Association.; Recombine

Grant/Research Support: Pfizer Inc.; Aegerion Pharmaceuticals Inc.

Speaker's Bureau: Alexion Pharmaceuticals, Inc.; Amgen Inc.; AstraZeneca; Genzyme Corporation; Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; True Health Diagnostics

Non-faculty: Timothy Hayes, MD, PhD; Emma Gilmartin; and Chelsey Benedek hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Amgen, Inc.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact admin@academiccme.com.


Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications. 

Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit(s)™
  • 2.00 Non-physician
Course opens: 
06/29/2017
Course expires: 
06/28/2018
Rating: 
0

Available Credit

  • 2.00 AMA PRA Category 1 Credit(s)™
  • 2.00 Non-physician

Accreditation Period

Course opens: 
06/29/2017
Course expires: 
06/28/2018
Please login or register to take this course.